Total voting rights

Total number of voting rights and share capital in Novo Nordisk A/S as of 31 March 2008.

In accordance with Section 6 of the Danish Statutory Order on Issuers Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk as per the end of the month where changes have occurred.

Referring to Stock Exchange Announcement no 15/2008 dated 12 March 2008 announcing the result of the ordinary Annual General Meeting, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk as per 31 March 2008. The adoption of agenda item 6.5.1 at the Annual General Meeting on 12 March 2008 means that following the Annual General Meeting each B share of DKK 1.00 (the present denomination of Novo Nordisk's shares) will carry 100 votes and each A share of DKK 1.00 will carry 1,000 votes. The voting ratio between the A and B shares has not been affected by the change.

+-------------------------------------------------------------------+
|          |     Number of shares | Nominal value | Number of votes |
|          |       (nominal value |         (DKK) |                 |
|          |               DKK 1) |               |                 |
|----------+----------------------+---------------+-----------------|
|          |                      |               |                 |
| A shares |                      |   107,487,200 | 107,487,200,000 |
|          |          107,487,200 |               |                 |
|----------+----------------------+---------------+-----------------|
|          |                      |               |                 |
| B shares |                      |   539,472,800 |                 |
|          |          539,472,800 |               |  53,947,280,000 |
+-------------------------------------------------------------------+

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

For further information please contact:

Media:                 Investors:

Outside North America: Outside North America:
Elin K Hansen          Mads Veggerby Lausten
Tel: (+45) 4442 3450   Tel: (+45) 4443 7919
 ekh@novonordisk.com      mlau@novonordisk.com 

                       Hans Rommer
                       Tel: (+45) 4442 4765
                        hrmm@novonordisk.com 

In North America:      In North America:
Sean Clements          Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
 secl@novonordisk.com     cqfr@novonordisk.com 

Stock Exchange Announcement no 18 / 2008

Copyright © Hugin AS 2008. All rights reserved.